Lauras Labs launches pregabalin capsules in US market

Hyderabad-based Laurus Labs, a leading R&D-driven pharmaceutical company in India, has announced the launch of the generic version of Lyrica, (pregabalin) capsules in US market.

Pregabalin is used to treat nerve pain in people with diabetes (diabetic neuropathy), herpes zoster (post-herpetic neuralgia), or spinal cord injury. The said medicine is also used with other medications to treat partial onset seizures in adults and children who are at least 4 years old.

As per IMS Health data, the said medicine is having sales of around US$5497 million in US markets for year ending March 2019.

For the year ended March 31, 2019, on a consolidated basis, the company reported a fall of 44.06 per cent in its net profit at Rs. 93.76 crore as compared to Rs. 167.61 crore for the previous year. Meanwhile, the total income of the company increased by 10 per cent at Rs. 2,308.07 crore for year as compared to Rs. 2,098.20 crore for the year ended March 31, 2018.

On Monday, the stock of Laurus Labs opened at Rs. 348 per share and made an intraday high of Rs. 349.60 on the BSE. The stock had hit its 52-week high of Rs. 472.95 on August 3, 2018 and 52-week low of Rs. 322.05 on June 20, 2019 on the BSE.